Priavoid is a biotechnology company developing orally available all-D-peptide therapeutics that target and disassemble toxic protein aggregates implicated in neurodegenerative diseases
Priavoid is a biotechnology company developing orally available all-D-peptide therapeutics that target and disassemble toxic protein aggregates implicated in neurodegenerative diseases. Its lead candidate is in Phase 2 development for Alzheimer’s disease, with additional programs targeting synucleinopathies and tau-related disease.